ClinicalTrials.gg
RecruitingNCT07588360Updated Jun 10, 2026

Haplo-Cord HSCT for AML/MDS

An interventional study of haplo-cord HSCT and Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX) in MDS (Myelodysplastic Syndrome) and AML (Acute Myeloid Leukemia), sponsored by Fujian Medical University Union Hospital. Recruiting at 4 sites in China. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Fujian Medical University Union Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2025, registered Apr 2026).
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
14 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 191 studies testing fludarabine in Leukemia, Myeloid, Acute — 34 open to participants now, 49 under way, 4 of them phase 3. fludarabine · Leukemia, Myeloid, Acute.

Planned enrollment
46th of 188
82 · median 47
Started
2025
with 6 others
No phase
13 of 191
2 open now
Primary completion
2028-10
later than 30 of 48 live
Registered
186th of 191
by date

Among the 191 studies testing fludarabine in Leukemia, Myeloid, Acute, this one is the 46th largest by planned enrollment of the 188 interventional ones that give a count, is one of 7 that started in 2025, is one of 13 with no phase, reaches primary completion later than 30 of the 48 other live ones, and was the 186th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

34 of the 191 studies testing fludarabine in Leukemia, Myeloid, Acute are open now, in 4 countries. Recruiting first, the newest first:

28 more — sign in →

By country, each count listing its studies:

All 34 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 14 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 191 studies testing fludarabine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so as to provide new evidence for clinical practice.

Specific research objectives I. To evaluate the efficacy of haploidentical-cord blood hematopoietic stem cell transplantation for AML and high-risk MDS, including the speed of hematopoietic recovery, immune tolerance, and long-term survival rates.

II. To compare the effects of different engraftment patterns (haploidentical engraftment vs. cord blood engraftment) on quality of life, immune tolerance, early complications, and long-term prognosis.

III. To identify the clinical advantages and indications of haploidentical-cord blood transplantation through data analysis, and to provide a theoretical basis for clinical decision-making.

Novelty of the Study I. Innovation in Hematopoietic Stem Cell Infusion Schedule The present study employs a sequential infusion strategy: haploidentical stem cells are infused on Day 0, and umbilical cord blood cells are infused on Day +6 after transplantation.In contrast to the conventional approach used at most domestic and international centers (including the uzhou Protocol), in which both stem cell sources are infused simultaneously on Day 0, the current protocol delays cord blood infusion. This design confers potential advantages for immune reconstitution and long-term cord blood engraftment.

II. Unique Myeloablative Conditioning Regimen

The conditioning regimen used in this study is as follows:

Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days.

(For patients in complete remission (CR) with negative MRD before transplantation, Fludarabine and Cytarabine are administered for 3 days instead of 5 days.) Distinct from regimens at other centers, our team administers cyclophosphamide within the critical window after haploidentical stem cell infusion but before cord blood infusion, establishing a novel sequential conditioning model. This approach balances myeloablative intensity and immunomodulation, creating a favorable environment for subsequent long-term cord blood engraftment.

III. Engraftment Outcomes and Clinical Value Preliminary clinical experience demonstrates that haplo-cord sequential transplantation following the FA5Cy2Bu3 conditioning regimen combined with low-dose ATG/PTCY can achieve long-term cord blood engraftment in approximately 50% of patients.

By comparison, other domestic protocols (e.g., the Suzhou Protocol) rarely result in sustained cord blood engraftment.

Achievement of long-term cord blood engraftment is clinically meaningful for reducing relapse rates, lowering the incidence and severity of graft-versus-host disease (GVHD), and improving patient prognosis. These outcomes represent a key advantage of the present protocol.

Read the detailed description

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) are common and rapidly progressive malignant hematologic disorders associated with poor prognosis without effective intervention. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only first-line therapeutic strategy with curative potential for long-term remission or even definitive cure. However, the efficacy of conventional transplantation approaches is limited by multiple factors, particularly the management of graft-versus-host disease (GVHD) and disease recurrence. Balancing the graft-versus-leukemia (GVL) effect against residual leukemia while effectively mitigating GVHD represents an unresolved challenge in current transplantation strategies.

Although an HLA-matched donor is the optimal choice, access to such donors is restricted by time constraints and availability. In recent years, the widespread use of haploidentical donors has dramatically improved transplant accessibility, enabling nearly all patients to identify a suitable donor. China has emerged as a global leader in the development and application of haploidentical transplantation. Nevertheless, the established Beijing Protocol and the Baltimore post-transplantation cyclophosphamide (PTCY) regimen each have distinct limitations: the former is associated with high engraftment rates and low relapse incidence but a relatively high rate of chronic GVHD (approximately 20%), whereas the latter reduces GVHD risk but carries higher rates of engraftment failure and disease relapse.

Umbilical cord blood transplantation (UCBT) represents an alternative donor source, whose inherent immune properties offer the potential to reduce GVHD while preserving the GVL effect. However, the limited cell dose in single cord blood units results in delayed hematopoietic reconstitution, high infection rates, and elevated early mortality, restricting its broader application in adult patients.

Against this background, transplantation strategies combining the advantages of different donor sources have become a major research focus. The 'haplo-cord hematopoietic stem cell transplantation' strategy, which combines haploidentical peripheral blood stem cells with unrelated umbilical cord blood stem cells, has been proposed. This approach integrates the rapid hematopoietic engraftment of haploidentical stem cells with the immunomodulatory properties of cord blood, thereby accelerating hematopoietic recovery and reducing the risk of acute and chronic GVHD. Furthermore, the incorporation of immunomodulatory agents such as low-dose anti-thymocyte globulin (ATG) and post-transplantation cyclophosphamide (PTCY) has led to simultaneous control of both transplantation-related mortality and relapse.

Domestic investigators reported that patients with relapsed/refractory acute leukemia (r/r-AL) who received combined haplo-HSCT and UCB-assisted transplantation exhibited superior leukemia-free survival and lower relapse rates compared with haploidentical transplantation alone, with 2-year overall survival, progression-free survival, cumulative incidence of relapse, and non-relapse mortality of 35.5%, 35.5%, 25.9%, and 38.0%, respectively. An international study comparing double UCBT (dUCBT) with haplo-cord transplantation for hematologic malignancies demonstrated that haplo-cord transplantation was associated with faster neutrophil and platelet engraftment, lower risks of grade II-IV acute GVHD and chronic GVHD, reduced relapse risk, and superior GVHD- and relapse-free survival compared with dUCBT.

In recent years, with the increasing incidence of AML and MDS, post-transplant relapse has become the primary obstacle to long-term therapeutic success. International multicenter data indicate that disease relapse remains the leading cause of transplant failure (59% for matched sibling donors vs. 51% for unrelated donors), followed by severe GVHD and infection. Although conventional strategies including re-induction chemotherapy, second transplantation, and donor lymphocyte infusion (DLI) have been explored, their efficacy is limited by high relapse rates, severe toxicities, and modest survival benefits, failing to meet current clinical needs.

Therefore, the development of novel transplantation models that enhance GVL while controlling GVHD has become an urgent bottleneck to address. Combined donor transplantation strategies represent one promising approach toward this goal. To date, several countries have conducted exploratory studies of the haplo-cord regimen, reporting faster hematopoietic recovery, lower rejection risk, and reduced relapse rates. Multiple centers in China have also initiated clinical validation with encouraging results.

The applicant's research team has developed and implemented a haplo-cord HSCT protocol based on low-dose ATG plus PTCY, with proven safety and efficacy in clinical practice. Compared with conventional haploidentical or single cord blood transplantation, this regimen achieved significantly higher relapse-free survival in patients with relapsed/refractory disease, effectively reduced the incidence of chronic GVHD, and improved quality of life and survival expectancy, with 2-year overall survival, disease-free survival, and GVHD- and relapse-free survival of 64.9%, 64.5%, and 60.8%, respectively. Notably, nearly half of the patients achieved dominant cord blood engraftment, challenging the traditional view that cord blood serves only an auxiliary role.

In the present prospective multicenter cohort study, we aim to further investigate the long-term efficacy of this combined transplantation strategy in patients with AML and high-risk MDS. By comparing immune reconstitution, relapse rates, GVHD, and other prognostic outcomes between cord blood-dominant and haploidentical-dominant engraftment, we intend to define its optimal indications and establish high-level evidence to optimize hematopoietic stem cell transplantation regimens.

This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so as to provide new evidence for clinical practice.

Specific research objectives: 1. To evaluate the efficacy of haploidentical-cord blood hematopoietic stem cell transplantation for AML and high-risk MDS, including the speed of hematopoietic recovery, immune tolerance, and long-term survival rates. 2. To compare the effects of different engraftment patterns (haploidentical engraftment vs. cord blood engraftment) on quality of life, immune tolerance, early complications, and long-term prognosis. 3. To identify the clinical advantages and indications of haploidentical-cord blood transplantation through data analysis, and to provide a theoretical basis for clinical decision-making.

03

Conditions studied

  • MDS (Myelodysplastic Syndrome)
  • AML (Acute Myeloid Leukemia)

Keywords

  • Acute Myeloid Leukemia(AML)
  • Myelodysplastic Syndrome(MDS)
  • haplo-cord HSCT
04

Who can participate

Ages eligible
14 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 14 and 60 years, with no gender restriction.
  • Intermediate- or high-risk AML in first complete remission (CR1).
  • AML in second or subsequent complete remission (≥ CR2).
  • AML.
  • Low-risk AML meeting any of the following: Failure to achieve a ≥3-log reduction in RUNX1::RUNX1T1 transcript level compared with baseline after 2 consolidation cycles, or loss of major molecular remission (MMR) within 6 months; CBFB::MYH11/ABL ratio > 0.1% at any time point after 2 consolidation cycles in patients with CBFB::MYH11-rearranged AML; Presence of D816 KIT mutation in patients with CBFB::MYH11-rearranged AML; Flow cytometry-positive MRD at any time point after 2 consolidation cycles in patients with CEBPA double-mutant AML; Persistently positive MRD after chemotherapy in patients with NPM1-mutated AML.
  • Intermediate-2 or high-risk MDS according to the IPSS scoring system.
  • Adequate general health status and ability to tolerate hematopoietic stem cell transplantation.
  • Provision of signed and willingness to comply with study-required follow-up and examinations.

Exclusion criteria

Exclusion Criteria:

  • Prior history of other hematopoietic stem cell transplantation.
  • History of ex vivo T-cell-depleted stem cell transplantation.
  • Survival duration of less than 1 month after transplantation.
  • Severe organ dysfunction, including significant impairment of hepatic, renal, cardiac, or pulmonary function.
  • Active severe infection, such as uncontrolled pneumonia, sepsis, or other systemic infections.
  • History of severe reactions to study medications, including cyclophosphamide or anti-thymocyte globulin (ATG).
  • Presence of severe psychiatric disorders or cognitive impairment that precludes compliance with study treatment and follow-up.
  • Pregnant or lactating women.
  • Concurrent of other organ system.
  • Any other medical conditions deemed inappropriate for study participation by the treating investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Haplo-Cord HSCT

    Procedure: haplo-cord HSCT · Drug: Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)

Interventions

  • Procedurehaplo-cord HSCT

    Patients with disease status in CR and MRD-negative before transplantation received the FA3Cy2Bu3 regimen: Fludarabine 25 mg/m² for 3 days, Cytarabine 2 mg/m² for 3 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. All other patients received the FA5Cy2Bu3 regimen: Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. Following the conditioning regimen, patients underwent haploidentical-cord blood hematopoietic stem cell transplantation. Haploidentical hematopoietic stem cells were infused on day 0, and umbilical cord blood hematopoietic stem cells were infused on day 6.

  • DrugFludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)

    Drug pages: FludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · BusulfanStudies of BusulfanBusulfan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Antilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · MelphalanStudies of MelphalanMelphalan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients with disease status in CR and MRD-negative before transplantation received the FA3Cy2Bu3 regimen: Fludarabine 25 mg/m² for 3 days, Cytarabine 2 mg/m² for 3 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. All other patients received the FA5Cy2Bu3 regimen: Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. Following the conditioning regimen, patients underwent haploidentical-cord blood hematopoietic stem cell transplantation. Haploidentical hematopoietic stem cells were infused on day 0, and umbilical cord blood hematopoietic stem cells were infused on day 6.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: 3 years after transplantation

Secondary outcomes

  1. Progression-Free Survival(PFS)

    Time frame: 3 years after transplantation

  2. Disease-Free Survival(DFS)

    Time frame: 3 years after transplantation

  3. GVHD and Relapse-Free Survival(GRFS)

    Time frame: 3 years after transplantation

  4. Non-Relapse Mortality(NRM)

    Time frame: 3 years after transplantation

07

Study locations

1 of 4 sites recruiting
08

References and documents

Publications

  • Li H, Li X, Chen Y, Li D, Chen X, Zhu Z, Wang Y, Huang J, Chen P, Chen Y, Li N. Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies. Front Immunol. 2021 Nov 4;12:733326. doi: 10.3389/fimmu.2021.733326. eCollection 2021. PubMed 34804017 ↗
  • Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer. 2015 Aug 1;121(15):2517-28. doi: 10.1002/cncr.29383. Epub 2015 Apr 17. PubMed 25891003 ↗
  • Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53. PubMed 28665419 ↗
  • Chen EL, Liu HL, Geng LQ, Tang BL, Zhu XY, Yao W, Song KD, Wan X, Sun GY, Qiang P, Fan Q, Zhou ZW, Zheng CC, Zhang L, Zhang XH, Tong J, Sun ZM. [Unrelated cord blood stem cell transplantation for high-risk/refractory childhood acute myeloid leukemia: a clinical analysis of 160 cases]. Zhonghua Xue Ye Xue Za Zhi. 2021 Jul 14;42(7):549-554. doi: 10.3760/cma.j.issn.0253-2727.2021.07.004. Chinese. PubMed 34455741 ↗
  • Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PubMed 32247396 ↗
  • Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, Anderson BO, Aremu O, Artaman A, Asgedom SW, Assadi R, Atey TM, Avila-Burgos L, Awasthi A, Ba Saleem HO, Barac A, Bennett JR, Bensenor IM, Bhakta N, Brenner H, Cahuana-Hurtado L, Castaneda-Orjuela CA, Catala-Lopez F, Choi JJ, Christopher DJ, Chung SC, Curado MP, Dandona L, Dandona R, das Neves J, Dey S, Dharmaratne SD, Doku DT, Driscoll TR, Dubey M, Ebrahimi H, Edessa D, El-Khatib Z, Endries AY, Fischer F, Force LM, Foreman KJ, Gebrehiwot SW, Gopalani SV, Grosso G, Gupta R, Gyawali B, Hamadeh RR, Hamidi S, Harvey J, Hassen HY, Hay RJ, Hay SI, Heibati B, Hiluf MK, Horita N, Hosgood HD, Ilesanmi OS, Innos K, Islami F, Jakovljevic MB, Johnson SC, Jonas JB, Kasaeian A, Kassa TD, Khader YS, Khan EA, Khan G, Khang YH, Khosravi MH, Khubchandani J, Kopec JA, Kumar GA, Kutz M, Lad DP, Lafranconi A, Lan Q, Legesse Y, Leigh J, Linn S, Lunevicius R, Majeed A, Malekzadeh R, Malta DC, Mantovani LG, McMahon BJ, Meier T, Melaku YA, Melku M, Memiah P, Mendoza W, Meretoja TJ, Mezgebe HB, Miller TR, Mohammed S, Mokdad AH, Moosazadeh M, Moraga P, Mousavi SM, Nangia V, Nguyen CT, Nong VM, Ogbo FA, Olagunju AT, Pa M, Park EK, Patel T, Pereira DM, Pishgar F, Postma MJ, Pourmalek F, Qorbani M, Rafay A, Rawaf S, Rawaf DL, Roshandel G, Safiri S, Salimzadeh H, Sanabria JR, Santric Milicevic MM, Sartorius B, Satpathy M, Sepanlou SG, Shackelford KA, Shaikh MA, Sharif-Alhoseini M, She J, Shin MJ, Shiue I, Shrime MG, Sinke AH, Sisay M, Sligar A, Sufiyan MB, Sykes BL, Tabares-Seisdedos R, Tessema GA, Topor-Madry R, Tran TT, Tran BX, Ukwaja KN, Vlassov VV, Vollset SE, Weiderpass E, Williams HC, Yimer NB, Yonemoto N, Younis MZ, Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2018 Nov 1;4(11):1553-1568. doi: 10.1001/jamaoncol.2018.2706. PubMed 29860482 ↗
  • MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, DeFor TE, Verneris MR, Blazar BR, Wagner JE. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood. 2009 Mar 12;113(11):2410-5. doi: 10.1182/blood-2008-07-163238. Epub 2008 Nov 7. PubMed 18997171 ↗
  • Gomez-Arteaga A, Orfali N, Guarneri D, Cushing MM, Gergis U, Hsu J, Hsu YS, Mayer SA, Phillips AA, Chase SA, Mokhtar AE, Shore TB, Van Besien K. Cord blood transplants supported by unrelated donor CD34+ progenitor cells. Bone Marrow Transplant. 2020 Dec;55(12):2298-2307. doi: 10.1038/s41409-020-0959-5. Epub 2020 Jun 9. PubMed 32518291 ↗
  • Yun HD, Varma A, Hussain MJ, Nathan S, Brunstein C. Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation. J Clin Med. 2019 Nov 14;8(11):1968. doi: 10.3390/jcm8111968. PubMed 31739455 ↗
  • Hiwarkar P, Qasim W, Ricciardelli I, Gilmour K, Quezada S, Saudemont A, Amrolia P, Veys P. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015 Dec 24;126(26):2882-91. doi: 10.1182/blood-2015-06-654780. Epub 2015 Oct 8. PubMed 26450984 ↗
  • Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, Witherspoon R, Mielcarek M, Deeg JH, Sorror M, Dahlberg A, Sandmaier BM, Salit R, Petersdorf E, Appelbaum FR, Delaney C. Cord-Blood Transplantation in Patients with Minimal Residual Disease. N Engl J Med. 2016 Sep 8;375(10):944-53. doi: 10.1056/NEJMoa1602074. PubMed 27602666 ↗
  • Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, Ayuk F, Christopeit M, Kroger N. Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation. Haematologica. 2022 Apr 1;107(4):857-867. doi: 10.3324/haematol.2020.271445. PubMed 33832208 ↗
  • Battipaglia G, Labopin M, Kroger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itala-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019 Sep 12;134(11):892-899. doi: 10.1182/blood.2019000487. Epub 2019 Jul 3. PubMed 31270102 ↗
  • Lv M, Chang YJ, Huang XJ. Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 Aug;54(Suppl 2):703-707. doi: 10.1038/s41409-019-0605-2. PubMed 31431695 ↗
  • Xu LP, Wu DP, Han MZ, Huang H, Liu QF, Liu DH, Sun ZM, Xia LH, Chen J, Wang HX, Wang C, Li CF, Lai YR, Wang JM, Zhou DB, Chen H, Song YP, Liu T, Liu KY, Huang XJ. A review of hematopoietic cell transplantation in China: data and trends during 2008-2016. Bone Marrow Transplant. 2017 Nov;52(11):1512-1518. doi: 10.1038/bmt.2017.59. Epub 2017 Apr 24. PubMed 28436973 ↗
  • Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, Kodera Y. Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016 Jan;22(1):23-6. doi: 10.1016/j.bbmt.2015.11.001. Epub 2015 Nov 10. PubMed 26551633 ↗
  • Shouval R, Fein JA, Labopin M, Kroger N, Duarte RF, Bader P, Chabannon C, Kuball J, Basak GW, Dufour C, Galimard JE, Polge E, Lankester A, Montoto S, Snowden JA, Styczynski J, Yakoub-Agha I, Mohty M, Nagler A. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019 Nov;6(11):e573-e584. doi: 10.1016/S2352-3026(19)30158-9. Epub 2019 Aug 30. PubMed 31477550 ↗
  • Canaani J, Beohou E, Labopin M, Ghavamzadeh A, Beelen D, Hamladji RM, Niederwieser D, Volin L, Markiewicz M, Arnold R, Mufti G, Ehninger G, Socie G, Kroger N, Mohty M, Nagler A. Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis. J Intern Med. 2019 Apr;285(4):407-418. doi: 10.1111/joim.12854. Epub 2018 Nov 16. PubMed 30372796 ↗

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: Beginning 3 months and ending 3 years after the publication of results

Access criteria: Access to de-identified IPD and supporting documents will be available to all researchers upon application to the principal investigator. Approval will be granted following review, and data will be provided via direct contact with the study team.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.

Of 132 non-industry interventional studies with no phase under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 128. This study's planned 36 months is below that.

Counting every sponsor, half of 139 studies reached it within 47 months; a quarter within 25 and three quarters within 123.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 14, 2026
StartActual
Oct 20, 2025
Primary completionEst.
Oct 20, 2028
CompletionEst.
Jun 30, 2029
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07588360
Responsible party
Sponsor
First posted
May 14, 2026
Start date
Oct 20, 2025
Primary completion
Oct 20, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jun 10, 2026

Study contacts

Nainong Li, MD
Contact
nainli@aliyun.com
+86 13365910189
Lihua Wu, MD
Contact
877998423@qq.com
+86 18359180265

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cytarabine · Busulfan · Antilymphocyte Serum · Melphalan · Cyclophosphamide

Start the discussion